Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation

Liver International

Volumn 30, Issue 2, 2010, Pages 334-335

  Cholongitas, Evangelos ^a   Vibhakorn, Shusang ^a   Lodato, Francesca ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DRUG EFFECT; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERTENSION; INFLAMMATION; LABORATORY TEST; LETTER; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RECURRENT INFECTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE;

EID: 77950618056     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02059.x     Document Type: Letter

References (3)

1. Corey KE, Shah N, Misdraji J. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009, 29:748-53.
2. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007, 14((Suppl. 1)):89-96.
3. Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007, 83:1141-50.